Beijing Xunsheng Biomedical Research Co., Ltd.

I. Phase Ia Dose Escalation Phase 1. Primary Objectives: 1) To evaluate the safety and tolerability of AVL-102 injection in patients; 2) To determine the recommended extended dose (RDE) and the recommended dose for Phase II clinical trials (RP2D). 2. Secondary Objectives: 1) To evaluate the antigen-specific antibody and cell-mediated immune responses induced by different dose levels; 2) To preliminarily evaluate the efficacy of different dose levels in treating patients with HPV16/18/52/58 infection-related high-grade intraepithelial lesions. 3. Exploratory Objectives: 1) To explore PK characteristics; 2) To explore the levels of relevant cytokines in peripheral blood after administration. II. Phase Ib Dose Expansion Phase 1. Primary Objective: To evaluate the efficacy of AVL-102 injection in patients. 2. Secondary Objectives: 1) To evaluate safety and tolerability; 2) To evaluate whether the corresponding dosing regimen at the RP2D dose level can induce antigen-specific antibodies against HPV16/18/52/58 and cell-mediated immune responses. 3. Exploratory purpose: To explore the levels of relevant cytokines in peripheral blood before and after drug administration.

Primary Objectives: 1. To evaluate the safety and tolerability of AVL-101 injection in patients with CIN2/3 caused by untreated human papillomavirus (HPV) 16/18 infection. 2. To determine the recommended dose (RP2D) for the Phase II clinical trial and to preliminarily develop a reasonable dosing regimen. Secondary Objectives: 1. To evaluate whether administration of different dose levels of AVL-101 injection, administered three times at 3-week intervals, can induce anti-HPV16/18 antigen-specific antibodies and cell-mediated immune responses. 2. To preliminarily evaluate the efficacy of different dose levels of AVL-101 injection administered three times at 3-week intervals for the treatment of CIN2/3 caused by HPV16/18 infection. Exploratory Objectives: 1. To explore the PK characteristics, i.e., DNA exposure level, of subjects after the first administration of AVL-101 injection. 2. To explore the levels of relevant cytokines in peripheral blood before and after administration of AVL-101 injection.

Primary objective: To evaluate the safety and efficacy of ReT01 injection in the treatment of advanced cervical cancer. Secondary objective: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of ReT01 ACT injection administered to patients with advanced cervical cancer.